Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the findings of an analysis of nivolumab (Opdivo) in Asian versus Western patients with gastric/gastroesophageal junction (GEJ) cancer.
Ian Chau, MD
Advertisement
Articles by Ian Chau, MD
Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses an analysis of Asian and Western patients with chemotherapy-refractory gastric/gastroesophageal junction (GEJ) cancer.
Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses finding with the combination of ramucirumab (Cyramza) plus pembrolizumab (Keytruda) in gastric or gastroesophageal (GEJ) cancer.
Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the tolerability of ramucirumab (Cyramza) plus pembrolizumab (Keytruda) in gastric or gastroesophageal (GEJ) cancer.
Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the CheckMate 577 study in resected lower esophageal or gastroesophageal junction (GEJ) cancer.
Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab.
Advertisement
Latest Updated Articles
Dr. Chau on CheckMate577 Study in Esophageal/GEJ CancerPublished: March 10th 2017 | Updated:
Dr. Chau on the Tolerability of Ramucirumab Plus Pembrolizumab in Gastric/GEJ CancerPublished: January 23rd 2018 | Updated:
Dr. Chau on Findings of Ramucirumab Plus Pembrolizumab in Gastric/GEJ CancerPublished: February 9th 2018 | Updated:
Dr. Chau on Analysis of Asian and Western Patients With Gastric/GEJ CancerPublished: February 22nd 2018 | Updated:
Dr. Chau on Nivolumab in Asian Versus Western Patients With Gastric/GEJ CancerPublished: March 14th 2018 | Updated:
Dr. Chau on Ramucirumab Plus Pembrolizumab for Gastric/GEJ CancerPublished: January 21st 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5